$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000082787119000013 Filed on May 07, 2019

Income Statement

Concept	2019 Q1	2018 Q1
Revenue	$49.79M	$46.63M
YoY Change	6.78%	-39.28%
Cost Of Revenue	$9.554M	$7.223M
YoY Change	32.27%	-32.9%
Gross Profit	$36.69M	$34.82M
YoY Change	5.36%	-47.27%
Gross Profit Margin	73.69%	74.68%
Selling, General & Admin	$18.14M	$15.19M
YoY Change	19.4%	-18.22%
% of Gross Profit	49.45%	43.64%
Research & Development	$6.375M	$17.32M
YoY Change	-63.19%	130.17%
% of Gross Profit	17.38%	49.74%
Depreciation & Amortization	$242.0K	$341.0K
YoY Change	-29.03%	73.98%
% of Gross Profit	0.66%	0.98%
Operating Expenses	$37.62M	$44.32M
YoY Change	-15.13%	0.51%
Operating Profit	$12.17M	$2.305M
YoY Change	427.94%	-92.95%
Interest Expense	$686.0K	$675.0K
YoY Change	1.63%	2400.0%
% of Operating Profit	5.64%	29.28%
Other Income/Expense, Net	-$192.0K	-$648.0K
YoY Change	-70.37%	2600.0%
Pretax Income	$11.98M	$1.657M
YoY Change	622.81%	-94.93%
Income Tax	$3.004M	-$959.0K
% Of Pretax Income	25.08%	-57.88%
Net Earnings	$8.973M	$2.616M
YoY Change	243.0%	-88.59%
Net Earnings / Revenue	18.02%	5.61%
Basic Earnings Per Share	$0.64	$0.18
Diluted Earnings Per Share	$0.62	$0.17
COMMON SHARES
Basic Shares Outstanding	13.93M shares	14.82M shares
Diluted Shares Outstanding	14.42M shares	15.48M shares

Balance Sheet

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$102.1M	$95.70M
YoY Change	6.69%	245.49%
Cash & Equivalents	$102.1M	$95.67M
Short-Term Investments
Other Short-Term Assets	$401.0K	$580.0K
YoY Change	-30.86%	-52.26%
Inventory	$10.27M	$6.141M
Prepaid Expenses
Receivables	$63.93M	$53.43M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$182.2M	$168.8M
YoY Change	7.94%	36.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.333M	$6.498M
YoY Change	-64.1%	71.18%
Goodwill	$39.74M	$39.74M
YoY Change	0.0%	0.0%
Intangibles	$17.47M	$22.65M
YoY Change	-22.86%	-30.64%
Long-Term Investments
YoY Change
Other Assets	$3.565M	$106.0K
YoY Change	3263.21%	-82.85%
Total Long-Term Assets	$77.22M	$80.48M
YoY Change	-4.04%	-20.52%
TOTAL ASSETS
Total Short-Term Assets	$182.2M	$168.8M
Total Long-Term Assets	$77.22M	$80.48M
Total Assets	$259.5M	$249.3M
YoY Change	4.07%	10.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.79M	$9.353M
YoY Change	79.47%	-50.84%
Accrued Expenses	$22.44M	$13.10M
YoY Change	71.24%	-14.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.000M	$6.250M
YoY Change	-20.0%
Total Short-Term Liabilities	$44.22M	$28.76M
YoY Change	53.76%	-18.84%
LONG-TERM LIABILITIES
Long-Term Debt	$37.00M	$41.62M
YoY Change	-11.11%
Other Long-Term Liabilities	$2.870M	$700.0K
YoY Change	310.0%	-96.9%
Total Long-Term Liabilities	$39.87M	$41.62M
YoY Change	-4.22%	84.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.22M	$28.76M
Total Long-Term Liabilities	$39.87M	$41.62M
Total Liabilities	$84.09M	$70.38M
YoY Change	19.47%	21.35%
SHAREHOLDERS EQUITY
Retained Earnings	$67.16M	$28.90M
YoY Change	132.39%	-1156.67%
Common Stock	$17.00K	$16.00K
YoY Change	6.25%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$153.9M	$87.80M
YoY Change	75.29%	73.32%
Treasury Stock Shares	2.590M shares	1.365M shares
Shareholders Equity	$175.4M	$178.2M
YoY Change
Total Liabilities & Shareholders Equity	$259.5M	$249.3M
YoY Change	4.07%	10.89%

Cashflow Statement

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	$8.973M	$2.616M
YoY Change	243.0%	-88.59%
Depreciation, Depletion And Amortization	$242.0K	$341.0K
YoY Change	-29.03%	73.98%
Cash From Operating Activities	$26.18M	$4.921M
YoY Change	432.03%	-139.57%
INVESTING ACTIVITIES
Capital Expenditures	$177.0K	$19.00K
YoY Change	831.58%	-97.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$177.0K	-$19.00K
YoY Change	831.58%	-97.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$7.003M
YoY Change	-100.0%	-48.71%
Debt Paid & Issued, Net	$2.500M	$0.00
YoY Change
Cash From Financing Activities	-$2.656M	-$23.89M
YoY Change	-88.88%	99.11%
NET CHANGE
Cash From Operating Activities	$26.18M	$4.921M
Cash From Investing Activities	-$177.0K	-$19.00K
Cash From Financing Activities	-$2.656M	-$23.89M
Net Change In Cash	$23.35M	-$18.99M
YoY Change	-222.97%	-24.38%
FREE CASH FLOW
Cash From Operating Activities	$26.18M	$4.921M
Capital Expenditures	$177.0K	$19.00K
Free Cash Flow	$26.00M	$4.902M
YoY Change	430.48%	-137.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13929470	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	EAGLE PHARMACEUTICALS, INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q4	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	5869000	USD
CY2019Q1	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	6881000	USD
CY2018Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1245000	USD
CY2019Q1	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1131000	USD
CY2018Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	2700000	USD
CY2019Q1	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	3256000	USD
CY2018Q4	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	9939000	USD
CY2019Q1	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	0	USD
CY2018Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-1518000	USD
CY2019Q1	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-4368000	USD
CY2019Q1	egrx	Number Of Products NumberOfProducts	2	product
CY2019Q1	egrx	Obligations Future Payments ObligationsFuturePayments	84684000	USD
CY2019Q1	egrx	Obligations Future Payments Due In Fifth Year ObligationsFuturePaymentsDueInFifthYear	485000	USD
CY2019Q1	egrx	Obligations Future Payments Due In Fourth Year ObligationsFuturePaymentsDueInFourthYear	583000	USD
CY2019Q1	egrx	Obligations Future Payments Due In Second Year ObligationsFuturePaymentsDueInSecondYear	5864000	USD
CY2019Q1	egrx	Obligations Future Payments Due In Third Year ObligationsFuturePaymentsDueInThirdYear	34333000	USD
CY2019Q1	egrx	Obligations Future Payments Due Remainder Of Fiscal Year ObligationsFuturePaymentsDueRemainderOfFiscalYear	43419000	USD
CY2019Q1	egrx	Obligations Future Payments Due Thereafter ObligationsFuturePaymentsDueThereafter	0	USD
CY2019Q1	egrx	Operating Lease Rightof Use Asset Depreciation OperatingLeaseRightofUseAssetDepreciation	261000	USD
CY2018Q1	egrx	Payments For Employee Options Exercised PaymentsForEmployeeOptionsExercised	3051000	USD
CY2018Q1	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	15001000	USD
CY2019Q1	egrx	Paymentsfor Contingent Consideration PaymentsforContingentConsideration	0	USD
CY2018Q4	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1540000	USD
CY2019Q1	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1266000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9917000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	16786000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	66486000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	63930000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23519000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22436000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2408000	USD
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2969000	USD
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7139000	USD
CY2019Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7195000	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5049000	USD
CY2019Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2108000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	256458000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	262084000	USD
CY2018Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3051000	USD
CY2019Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	198000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5305000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5782000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5305000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5782000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	94000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	94000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	670000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	630000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1985879	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2194399	shares
CY2018Q4	us-gaap	Assets Assets	238603000	USD
CY2019Q1	us-gaap	Assets Assets	259452000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	163844000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	182229000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	27000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78791000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102139000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114657000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95670000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78791000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102139000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18987000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23348000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16504283	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16519728	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7223000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9554000	USD
CY2019Q1	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	500000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	13822000	USD
CY2019Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	14109000	USD
CY2018Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-123000	USD
CY2019Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-287000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	341000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	503000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.17
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.62
CY2018Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.58
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.25
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6278000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5627000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	7556000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1890000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1369000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1369000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2623000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2666000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34320000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23100000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18103000	USD
CY2019Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17473000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	39743000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	39743000	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1657000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11977000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-959000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3004000	USD
CY2018Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	96000	USD
CY2019Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-6490000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2628000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6869000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-395000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2556000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2289000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1083000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1023000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1961000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	-18000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	263000	USD
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	658805	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	492984	shares
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18103000	USD
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	17473000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	675000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	686000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	368000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	625000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	225000	USD
CY2019Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	642000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	8304000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	10265000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6303000	USD
CY2019Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	7908000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1776000	USD
CY2019Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1715000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	27000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	494000	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	184000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3374000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	485000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	583000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	583000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	864000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	859000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	238603000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259452000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39686000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	44222000	USD
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	42500000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	6250000	USD
CY2019Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	33750000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	5000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	3750000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	38155000	USD
CY2019Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	36999000	USD
CY2018Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	895000	USD
CY2019Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	626000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-23889000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2656000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-177000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4921000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	8973000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-648000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-192000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26181000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	2616000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	8973000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2616000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	44321000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	37616000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	2305000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	12169000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	287000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2871000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	287000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2871000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3661000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1146000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	485000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	583000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	583000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	864000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1809000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2152000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	134000	USD
CY2019Q1	us-gaap	Other Assets Current OtherAssetsCurrent	401000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	694000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3565000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2870000	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7003000	USD
CY2019Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	198000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	177000	USD
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10263000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5895000	USD
CY2018Q4	us-gaap	Prepaid Insurance PrepaidInsurance	150000	USD
CY2019Q1	us-gaap	Prepaid Insurance PrepaidInsurance	883000	USD
CY2018Q4	us-gaap	Prepaid Taxes PrepaidTaxes	5739000	USD
CY2019Q1	us-gaap	Prepaid Taxes PrepaidTaxes	89000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1166000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2397000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2333000	USD
CY2019Q1	us-gaap	Purchase Obligation PurchaseObligation	38810000	USD
CY2019Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2019Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2019Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2019Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2019Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2019Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	38810000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2500000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17320000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6375000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	58187000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	67160000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46626000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49785000	USD
CY2018Q1	us-gaap	Royalty Expense RoyaltyExpense	4585000	USD
CY2019Q1	us-gaap	Royalty Expense RoyaltyExpense	3546000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15193000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18141000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5305000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5782000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4376
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5047
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0271
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0261
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0230
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0257
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	631625	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	550433	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2786568	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3068370	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2556365	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3092296	shares
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M22D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	215108	shares
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	9588	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1166000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	134715	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4914	shares
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	179144000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	178177000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	160762000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	175361000	USD
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2590258	shares
CY2019Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	2590258	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	2590258	shares
CY2018	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1348563	shares
CY2018Q4	us-gaap	Treasury Stock Value TreasuryStockValue	153900000	USD
CY2019Q1	us-gaap	Treasury Stock Value TreasuryStockValue	153900000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	153900000	USD
CY2018Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	7003000	USD
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	73100000	USD
CY2019Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	15478335	shares
CY2019Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	14418211	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15478335	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14418211	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14819530	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13925227	shares
CY2019Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2018 was derived from audited financial statements, but certain information and footnote disclosures normally included in the Company's annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on February 28, 2019. Unless otherwise indicated or required by context, reference throughout to the "Company," "Eagle Pharmaceuticals," "Eagle," "we," "us" or "our" mean Eagle Pharmaceuticals, Inc., a Delaware corporation and its subsidiary, Eagle Biologics, Inc., and references to "Eagle Biologics" mean Eagle Biologics, Inc.</font></div></div>
CY2019Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000827871-19-000013-index-headers.html	Edgar Link	pending
0000827871-19-000013-index.html	Edgar Link	pending
0000827871-19-000013.txt	Edgar Link	pending
0000827871-19-000013-xbrl.zip	Edgar Link	pending
egrx-20180930.xml	Edgar Link	completed
egrx-20180930.xsd	Edgar Link	pending
egrx-20180930_cal.xml	Edgar Link	unprocessable
egrx-20180930_def.xml	Edgar Link	unprocessable
egrx-20180930_lab.xml	Edgar Link	unprocessable
egrx-20180930_pre.xml	Edgar Link	unprocessable
egrx_q1x2019.htm	Edgar Link	pending
exhibit101.htm	Edgar Link	pending
exhibit311q12019.htm	Edgar Link	pending
exhibit312q12019.htm	Edgar Link	pending
exhibit321q12019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2019 Q1 Form 10-Q Financial Statement

#000082787119000013 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2019 Q1 Form 10-Q Financial Statement

#000082787119000013 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx